$3.11
-0.07 (-2.20%)
Open$3.14
Previous Close$3.18
Day High$3.18
Day Low$2.95
52W High$13.93
52W Low$1.90
Volume—
Avg Volume15.5K
Market Cap7.13M
P/E Ratio—
EPS$-1.63
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,074.6% upside
Current
$3.11
$3.11
Target
$36.53
$36.53
$23.38
$36.53 avg
$47.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.01M | 3.33M | 899.1K |
| Net Income | -3,609,566 | -2,700,647 | -268,437 |
| Profit Margin | -90.1% | -85.6% | -29.9% |
| EBITDA | -3,808,889 | -3,008,100 | -429,552 |
| Free Cash Flow | — | — | -251,567 |
| Rev Growth | +20.3% | +20.3% | -1.1% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |